Stem Cell Clinic

Cell and Tissue Culture Supplies Market Analysis with Market Size, Industry Share, trends and Forecast to 2026 – The Think Curiouser

By Stell Cell Research

The worldwide Cell and Tissue Culture Supplies Market statistical surveying report is an inescapable research report that contacts the most imperative parts of the Cell and Tissue Culture Supplies platform that is important to be gotten a handle on by an expert or even a layman. The research covers the current market size of theCell and Tissue Culture Supplies marketand its growth rates based on 5-year history data along with the company profile of key players/manufacturers such as Stemcell Technologies, Wheaton Industries, GE Healthcare, Thermo Fisher Scientific, VWR International, Merck KGaA, Lonza Group, Corning, Promocell GmbH, Eppendorf AG. The statistical surveying report illuminates one with respect to a few of the imperative perspectives, for example, an outline of the Cell and Tissue Culture Supplies item, the development factors improving or hampering its advancement, application in the different fields, major ruling organizations, veritable certainties, monetary circumstance, and topographical examination.

To Understand How Covid-19 impact on this industry. Get Free Sample Report:https://www.syndicatemarketresearch.com/sample/cell-and-tissue-culture-supplies-market.html

Based on the present techniques and trends, the global Cell and Tissue Culture Supplies market report provides a thoroughly analyzed and predicted forecast regarding the upcoming growth of the market. The report conjointly categorizes the market into the main product andthe sub-segments Vaccine Production, Biopharmaceutical Production, Toxicity Testing, Gene Therapy, Drug Screening Development, Cancer Research, Other of the Cell and Tissue Culture Supplies market is depicted in the report. The market report also explains the major alteration in the product version, its production technology, and development that may be caused due to a little variation in the product profile.

The global Cell and Tissue Culture Supplies market is one of the booming markets with a well-established zone worldwide. The global market has been completely focusing on the advancement in groundbreaking technologies and listening to the customers preferences; which lead to the vast and continuous increase in its growth rate. The global Cell and Tissue Culture Supplies market provides a huge platform with lots of opportunities for different industries in different regions to emerge and establish globally.

Read Detailed Index of full Research Study at::https://www.syndicatemarketresearch.com/market-analysis/cell-and-tissue-culture-supplies-market.html

The global report provides detailed key points that have significant effects on the global development of the Cell and Tissue Culture Supplies market. It provides the current status as well as future aspects over the market development. The report is generated after in-depth research and thorough analysis of the development in various sectors of the market that needs technological ideas, hypothetical analysis, and its applicability. The factors that significantly improve and demote the market growth; deep justification of the markets previous data; along with the current analyzed data; and the future development of the Cell and Tissue Culture Supplies market are included in the report. The Cell and Tissue Culture Supplies market report also delivers a theoretical-based study regarding the financial instabilities in terms of the demand and the supply.

There are 15 Chapters to display the Global Cell and Tissue Culture Supplies market

Chapter 1,Applications of Cell and Tissue Culture Supplies, Definition, Specifications, and Classification of Cell and Tissue Culture Supplies, Market Segment by Regions; Chapter 2,Manufacturing Process, Industry Chain Structure, Manufacturing Cost Structure, Raw Material, and Suppliers; Chapter 3,R&D Status and Technology Source, Technical Data and Manufacturing Plants Analysis of Cell and Tissue Culture Supplies, Capacity, and Commercial Production Date, Manufacturing Plants Distribution, Raw Materials Sources Analysis; Chapter 4,Overall Market Analysis, Capacity Analysis, Sales Analysis, Sales Price Analysis; Chapter 5 and 6,Regional Market Analysis that includes the United States, China, Europe, Japan, Korea & Taiwan, (by Type); Chapter 7 and 8,The Cell and Tissue Culture Supplies Segment Market Analysis (by Application) Major Manufacturers Analysis of Cell and Tissue Culture Supplies ; Chapter 9,Regional Market Trend, Market Trend Analysis, Market Trend by Product Type Consumable Products, Instruments, Market Trend by Application; Chapter 10,International Trade Type Analysis, Regional Marketing Type Analysis, Supply Chain Analysis; Chapter 11,The Consumers Analysis of Global Cell and Tissue Culture Supplies ; Chapter 12,Cell and Tissue Culture Supplies Research Findings and Conclusion, Appendix, methodology and data source; Chapter 13, 14, and 15,Cell and Tissue Culture Supplies sales channel, distributors, traders, dealers, Research Findings and Conclusion, Appendix, and data source.

Enquire Here Get customization&check discount for report @https://www.syndicatemarketresearch.com/inquiry/cell-and-tissue-culture-supplies-market

Reasons To Buy This Report:

To conclude, the Cell and Tissue Culture Supplies market report will provide the clients with a high-yielding market analysis assisting them to understand the market status and come up with new market avenues to capture hold of the market share.

About Us:

Syndicate Market Research has a range of research reports from various domains across the world. Our database of reports of various market categories and sub-categories would help to find the exact report you may be looking for.

Contact us:

Email ID:[emailprotected]

TOLL-FREE:+1 347 535 0815

Go here to see the original:
Cell and Tissue Culture Supplies Market Analysis with Market Size, Industry Share, trends and Forecast to 2026 - The Think Curiouser

Voters approve stem cell research bonds, but other health care measures defeated – State of Reform – State of Reform

By Stem Cell Treatment

Shawna De La Rosa | Nov 4, 2020

Californians voted on several health-related ballot measures including Proposition 23 which would require kidney dialysis clinics to have an on-site physician present while patients were being treated. The proposition was defeated in the election with a 64% no vote. The rejection of the measure is similar to the response to California Prop 8, which would have required dialysis clinics to issue refunds to patients for profits above 115% of the costs of direct patient care and health care improvements.

Proposition 14, which unofficially passed at 51% to 48.9%, will issue $5.5 billion in general obligation bonds for the California Institute for Regenerative Medicine, which was created to fund stem cell research. Proposition 71, which passed in 2004, issued $3 billion in bonds to finance CIRM. The current proposition requires that CIRM spends no more than 7.5% of bond funds on operational costs. The remaining funds will be spent on grants to groups that conduct trials, programs and research on stem cell treatments and for start-up costs for facilities. Californians for Stem Cell Research, Treatment and Cures led the campaign which received $16.62 million as of Oct. 17. Its largest donor was Robert N. Klein II, a real estate investor and stem cell research advocate.

Proposition 22, allows ride-hailing companies like Uber, Lyft, Doordash and Instacart to continue to treat its employees as independent contractors and not offer them health care and other benefits. The measure was approved by the voters by a 58% in favor and 42% opposed.

Proposition 15 would increase commercial property owners taxes for holdings of $3 million. The funds would be used for public health infrastructure, but the measure is still to close to call. The measureis trailing at 52% opposed with 100% of the precincts reporting. Community clinics, nurses and Planned Parenthood supported the measure hoping for funds to help rebuild the underfunded health care system.

View original post here:
Voters approve stem cell research bonds, but other health care measures defeated - State of Reform - State of Reform

Stem cells key to ALS therapy – Agoura Hills Acorn

By Stem Cell Treatment

By The Acorn Staff | on November 05, 2020

Twenty years ago, when stem cell therapy was highly regulated in the United States and other countries, it was well underway in the Hadassah Hospital labs in Jerusalem.

Never would we have imagined that the U.S. expansion of one of the key clinical trials conducted in our labs in Israel would be later funded by Californias Stem Cell Institute.

In 2004, California had the foresight to advance this critical area of research with the passage of Prop. 71 in 2004.

Stem cells replace damaged or diseased tissue. In this way, treatments or cures for diseases like age-related macular degeneration, ALS, MS, Parkinsons, Alzheimers and diabetes could be a reality in the foreseeable future.

I come to this subject from a place of personal sorrow. I watched my father-in-law, Irv, suffer for 12 years with ALS, a man I loved as if he were my own father. He fought hard. He made every minute of his battle meaningful, to soak up as much life as he could until he couldnt.

Hadassah researchers conducted the worlds first clinical trial using the patients own bone marrow stem cells to treat ALS. Expanded stem cell trials are now taking place here in California to treat ALS.

The California Stem Cell Agencys ALS funding has awarded a total of $79 million in grants to understand ALS and then to translate those discoveries into treatments and therapies. Two have already reached the clinical trial phase.

A Phase 1 clinical trial at Cedars-Sinai was funded to investigate the safety and efficacy of ways in which surviving neurons can be protected in people with ALS.

The second, a Phase 3 clinical trial at Brainstorm Cell Therapeutics, first began in Israel. The approach is to use mesenchymal stem cells derived from bone marrow boosted with protective factors to support and protect the neurons of ALS patients.

Stacey Dorenfeld Agoura Hills

Dorenfeld is the National State Advocacy co-chair and the Hadassah Southern California advocacy chair.

Read the original here:
Stem cells key to ALS therapy - Agoura Hills Acorn

Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. – UroToday

By Stem Cell Treatment

Bladder cancer (BLCA) is the fifth most common type of cancer worldwide, with high recurrence and progression rates. Although considerable progress has been made in the treatment of BLCA through accurate typing of molecular characteristics, little is known regarding the various genetic and epigenetic changes that have evolved in stem and progenitor cells. To address this issue, we have developed a novel stem cell typing method.

Based on six published genomic datasets, we used 26 stem cell gene sets to classify each dataset. Unsupervised and supervised machine learning methods were used to perform the classification.

We classified BLCA into three subtypes-high stem cell enrichment (SCE_H), medium stem cell enrichment (SCE_M), and low stem cell enrichment (SCE_L)-based on multiple cross-platform datasets. The stability and reliability of the classification were verified. Compared with the other subtypes, SCE_H had the highest degree of cancer stem cell concentration, highest level of immune cell infiltration, and highest sensitivity not only to predicted anti-PD-1 immunosuppressive therapy but also to conventional chemotherapeutic agents such as cisplatin, sunitinib, and vinblastine; however, this group had the worst prognosis. Comparison of gene set enrichment analysis results for pathway enrichment of various subtypes reveals that the SCE_H subtype activates the important pathways regulating cancer occurrence, development, and even poor prognosis, including epithelial-mesenchymal transition, hypoxia, angiogenesis, KRAS signal upregulation, interleukin 6-mediated JAK-STAT signaling pathway, and inflammatory response. Two identified pairs of transcription factors, GRHL2 and GATA6 and IRF5 and GATA3, possibly have opposite regulatory effects on SCE_H and SCE_L, respectively.

The identification of BLCA subtypes based on cancer stem cell gene sets revealed the complex mechanism of carcinogenesis of BLCA and provides a new direction for the diagnosis and treatment of BLCA.

Stem cell research & therapy. 2020 Oct 28*** epublish ***

Chaozhi Tang, Jiakang Ma, Xiuli Liu, Zhengchun Liu

Department of Urology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, China., Department of Oncology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450014, China., Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China., Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China. .

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33115513

Read the original post:
Development and validation of a novel stem cell subtype for bladder cancer based on stem genomic profiling. - UroToday

New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation – DocWire News

By Stem Cell Treatment

This article was originally published here

In Vivo. 2020 Nov-Dec;34(6):3545-3549. doi: 10.21873/invivo.12197.

ABSTRACT

BACKGROUND: Survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has increased but so have long-term sequelae. New-onset post-transplant diabetes mellitus (PTDM) occurs frequently following allo-HSCT.

PATIENTS AND METHODS: Study endpoints were incidence and risk factors of PDTM. We studied 599 adult patients suffering from either acute myeloid leukemia n=220), acute lymphoblastic leukemia (n=79), chronic myeloid leukemia (n=22), myelodysplastic syndrome/myeloproliferative neoplasm (n=105), chronic lymphocytic leukemia (n=37), lymphoma/myeloma (n=116, or non-malignant disorders (e.g. bone marrow failure, hemoglobinopathies) (n=20) who underwent myeloablative (466; 77.8%) or non-myeloablative (131; 21.9%) allo-HSCT between 2006 and 2016.

RESULTS: Altogether, 39 patients (6.5%) developed PTDM. In a competing-risk analysis, time to PTDM was associated with acute grade 2-4 graft-versus-host-disease (p=0.017). Further cardiovascular risk factors were hypertension (n=145; 24.2%), coronary artery disease (n=36, 6%), dyslipidemia (n=139; 23.3%), and stroke (n=12; 2%).

CONCLUSION: After allo-HSCT, a significant number of patients developed PTDM and patients with acute graft-versus-host-disease were found to have a higher risk for PTDM. Long-term and continuous follow-up for diabetes and cardiovascular risk factors after HSCT is important in order to be able to provide timely and appropriate treatment.

PMID:33144466 | DOI:10.21873/invivo.12197

Read the original:
New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation - DocWire News

Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL – OncLive

By Stem Cell Treatment

Ira Braunschweig, MD, director, Stem Cell Transplant Program, clinical program director, Hematologic Malignancies, Montefiore Medical Center, associate professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discusses factors to consider when selecting between autologous stem cell transplant (ASCT), allogeneic stem cell transplant (allo-SCT), and CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

In patients with chemotherapy-sensitive DLBCL, ASCT remains the standard of care, says Braunschweig. This is likely due to the fact that the field has decades worth of experience in treating this patient population with ASCT.

However, CAR T-cell therapy appears to be the clear treatment choice for patients with primary refractory DLBCL, Braunschweig explains.

Historically, patients who progressed after ASCT received an allo-SCT, which can have curative potential, says Braunschweig. However, many patients experience graft-versus-host disease and ongoing health issues following allo-SCT.

Alternatively, if patients can tolerate the toxicities that tend to arise within the first few weeks after CAR T-cell therapy, they have a decreased risk for long-term health issues compared with allo-SCT, Braunschweig says.

Moreover, unlike with transplant, CAR T-cell therapy eliminates the need to aggregate antitumor response, which may make it a more appealing option for patients, concludes Braunschweig.

Excerpt from:
Dr. Braunschweig on Selecting Between Transplant and CAR T-Cell Therapy in DLBCL - OncLive

Emerging Trends in Global Canine Stem Cell Therapy Market Report 2020,Deeply Analyzes Share, Types, Applications and Future Demands by Key Players-…

By Stem Cell Treatment

It is our aim to provide our readers with report forCanine Stem Cell Therapy Market, which examines the industry during the period 2020 2026. One goal is to present deeper insight into this line of business in this document. The first part of the report focuses on providing the industry definition for the product or service under focus in the Canine Stem Cell Therapy Market report. Next, the document will study the factors responsible for hindering and enhancing growth in the industry. After covering various areas of interest in the industry, the report aims to provide how the Canine Stem Cell Therapy Market will grow during the forecast period.

The major vendors covered:Aratana Therapeutics, Okyanos, Magellan Stem Cells, Stem Cell Vet, VetStem Biopharma, Medrego, Regeneus Ltd, MediVet Biologic, and Cell Therapy Sciences

The final report will add the analysis of the Impact of Covid-19 on Canine Stem Cell Therapy Market.

Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/global-canine-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=technoweekly&utm_medium=15

TheCanine Stem Cell Therapy Marketreport between the years 2020 2026 will highlight the current value of the industry. At the same time, there is also an estimate of how much this line of business will be worth at the end of the forecast period. As it is our goal to maintain high levels of accuracy at all times, we will take a look at the CAGR of the Canine Stem Cell Therapy Market. We make sure that all the information available in this report has excellent levels of readability. One way we achieve this target is by Canine Stem Cell Therapy Market segmentation. Going through the report for 2020 2026 will bring our readers up-to-date regarding this industry.

While examining the information from this document, one thing becomes clear, the elements which contribute to increase in demand for the product or service. At the same time, there will be a focus on what drives the popularity of these types of products or services. This report is for those who want to learn about Canine Stem Cell Therapy Market, along with its forecast for 2020 2026. Information regarding market revenue, competitive partners, and key players will also be available.

Segmentation

As discussed earlier, there is segmentation in theCanine Stem Cell Therapy Marketreport, to improve the accuracy and make it easier to collect data. The categories which are the dividing factors in the industry are distribution channels, application, and product or service type. With this level of segmentation, it becomes easier to analyze and understand the Canine Stem Cell Therapy Market. At the same time, there is emphasis on which type of consumers become the customers in this industry. When it comes to distribution channels, the Canine Stem Cell Therapy Market report looks at the different techniques of circulation of the product or service.

Regional Overview

In this part of theCanine Stem Cell Therapy Marketreport, we will be taking a look at the geographical areas and the role they play in contributing to the growth of this line of business. The areas of interest in this document are as follows Middle East and Africa, South and North America, Europe, and Asia Pacific. From the Canine Stem Cell Therapy Market report, it becomes clear which region is the largest contributor.

Latest Industry News

From thisCanine Stem Cell Therapy Marketreport, the reader will also get to learn about the latest developments in the industry. The reason is that these products or services have the potential to disrupt this line of business. If there is information about company acquisitions or mergers, this information will also be available in this portion of the Canine Stem Cell Therapy Market report.

If you have any special requirements about this Canine Stem Cell Therapy Market report, please let us know and we can provide custom report.

Inquire More About This Report @ https://www.reportsandmarkets.com/enquiry/global-canine-stem-cell-therapy-market-report-2020-by-key-players-types-applications-countries-market-size-forecast-to-2026-based-on-2020-covid-19-worldwide-spread?utm_source=technoweekly&utm_medium=15

About Us

ReportsAndMarkets.comallocates the globally available market research and many company reports from reputed market research companies that are a pioneer in their respective domains. We are completely an autonomous group and serve our clients by offering the trustworthy available research stuff, as we know this is an essential aspect of Market Research.

Contact Us

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

See the article here:
Emerging Trends in Global Canine Stem Cell Therapy Market Report 2020,Deeply Analyzes Share, Types, Applications and Future Demands by Key Players-...

Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 – PRnews Leader

By Stem Cell Treatment

AllTheResearch, now has a research study on the Canine Stem Cell Therapy market which delivers a precise summary of the industry estimates, SWOT analysis, industry size, profit estimation and regional outlook of the business. The report offers a concise estimation of future growth prospects and obstacles awaiting market players of this industry, while further examining their existing competitive settings and business strategies.

The global Canine Stem Cell Therapy market was valued at US$ 118.5 Mn in 2018 year and is expected to reach US$ 240.7 Mn in 2026, growing at a CAGR of 9.3% during the forecast period.

Key Questions Answered in the Report:

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/206

The research report on Canine Stem Cell Therapy market, covering the COVID-19 impact, provides a comparative analysis of the historical data with the current market scenario to unveil the growth projections for the industry over the analysis period. As per the study, the Canine Stem Cell Therapy market is expected to garner substantial returns and showcase a healthy growth rate throughout the forecast duration.

The Major Players Covered in Canine Stem Cell Therapy Market Study are:

Check all key players mentioned in this report. Lets connect with the analyst @ https://www.alltheresearch.com/speak-to-analyst/206

Major Segments Covered in Canine Stem Cell Therapy Market Reports are based on types and Applications as Follows:

Based on Types Canine Stem Cell Therapy Market Segmentation:

Based on Applications Canine Stem Cell Therapy Market Segmentation:

COVID-19 Impact on Canine Stem Cell Therapy Market:

The outbreak of COVID-19 has brought along a global recession, which has impacted several industries. Along with this impact COVID Pandemic has also generated few new business opportunities for Canine Stem Cell Therapy Market. Overall competitive landscape and market dynamics of Canine Stem Cell Therapy has been disrupted due to this pandemic. All these disruptions and impacts has been analysed quantifiably in this report, which is backed by market trends, events and revenue shift analysis. COVID impact analysis also covers strategic adjustments for Tier 1, 2 and 3 players of Canine Stem Cell Therapy Market.

Get Brief Information on Pre COVID-19 Analysis and Post COVID-19 Opportunities in Canine Stem Cell Therapy Market @https://www.alltheresearch.com/impactC19-request/206

How Report will help you to make decisions for business:

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference. While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also, same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email: [emailprotected]

Phone: +1 (407) 768-2028

Here is the original post:
Canine Stem Cell Therapy Market Size, Share Analysis by Manufacturers, Regions, Type and Application to 2026 - PRnews Leader

Stem Cell Therapy Market Insights Global Analysis and Forecast by (2020 2027) – The Think Curiouser

By Stem Cell Treatment

Emergen Research has published its latest report, titled Global Stem Cell Therapy Market, which is a unique compilation of the vital elements of the Stem Cell Therapy industry, including the key market growth drivers, constraints, opportunities, limitations, and threats. The micro- and macro-economic factors claimed to bolster the global market expansion in the near future have been encased in this report. The report consists of a broad database of the market dynamics intended to facilitate market estimation over the projected timeline. The latest report is highly beneficial for businesses and stakeholders looking forward to setting a robust footing in this industry.

The Global Stem Cell Therapy Market size was valued at USD 6.16 Billion in 2019 and is anticipated to reach USD 11.97 Billion by 2027 at a CAGR of 8.7%.

Request Sample copy of this [emailprotected] https://www.emergenresearch.com/request-sample-form/83

The top market competitors profiled in the report include Virgin Health Bank, Celgene Corporation, ReNeuron Group plc, Biovault Family, Precious Cells International Ltd., Mesoblast Ltd., Opexa Therapeutics, Inc., Caladrius, Neuralstem, Inc., and Pluristem, among others.

The Global Stem Cell Therapy Market report is dubbed as the first study encompassing the current situation of the Stem Cell Therapy market that is gravely impacted by the COVID-19 outbreak. The global health emergency has drastically affected the global economy, causing significant repercussions on this particular business sphere. The deadly viral outbreak and the subsequent global lockdown enforcement have beleaguered the Stem Cell Therapy business landscape. Moreover, it has impeded the developmental scope of various manufacturers and buyers involved in this sector. Thus, the report offers insightful speculations about the post-COVID-19 scenario of the Stem Cell Therapy industry.

Type Outlook (Revenue, USD Million; 2017-2027)

Application Outlook (Revenue, USD Million; 2017-2027)

End-User Outlook (Revenue, USD Million; 2017-2027)

The report thoroughly scrutinizes the Stem Cell Therapy market on the basis of the global market reach and consumer bases of the key geographical segments. Under the regional analysis, the report authors have studied the presence of the global Stem Cell Therapy market across the major regions and further highlighted their respective market shares, market sizes, revenue contributions, sales networks, distribution channels, and numerous other significant aspects.

To know more about the report, visit @ https://www.emergenresearch.com/industry-report/stem-cell-therapy-market

Stem Cell Therapy Market Segmentation by Region:

Competitive Outlook:

The latest research report involves an exhaustive study of the leading companies functioning mechanisms participating in this industry. According to our team of analysts, these companies hold a considerable portion of the overall Stem Cell Therapy market share. Under this section of the report, the principal strategic initiatives led by these companies, including mergers & acquisitions, joint ventures, new business deals, new product launches, collaborations, technological upgradation, and several others, have been emphasized.

Request customization of the report @ https://www.emergenresearch.com/request-for-customization-form/83

Key Report Coverage:

Frequently asked questions addressed in the report:

Request a discount on the report @ https://www.emergenresearch.com/request-discount-form/83

The rest is here:
Stem Cell Therapy Market Insights Global Analysis and Forecast by (2020 2027) - The Think Curiouser

Orchard Therapeutics’ gene therapy Strimvelis linked to a leukemia case – FiercePharma

By Stem Cell Treatment

The potential of gene therapies as cures for some hard-to-treat genetic diseases can be very attractive. But one such product is now suspected of causing a serious safety problem.

Friday, Orchard Therapeutics said its Strimvelis treatment, approved by European authorities in 2016 to treatthe rare inherited condition ADA-SCID, has been linked to a patients leukemia.

Preliminary findings suggest this diagnosis may be attributable to an insertional event related to treatment with Strimvelis, the company said. Its now investigating whether theres indeed a causal relationship.

Therapies requiring high volume injections are becoming more common across a broad range of therapeutic areas. For the growing category of injectables, multiple advances in pharmaceutical and device technologies play a role in achieving desired patient outcomes in adherence, safety and quality of life. This webinar will explore why adherence, safety and quality of life are important for patients, and how these key enablers contribute towards positive outcomes. We will also discuss existing challenges, such as drug development, regulatory, patient accessibility, and how device technologies can further improve patient outcomes. Save yor spot and register today!

Since its 2016 EU approvalwhen it was owned by original developer GlaxoSmithKlineonly 16 patients have been treated with Stimvelis. The patient who developed leukemia had apparently been treated under a GSK compassionate use program in 2016.

No more patients will get the therapy before the investigation is complete, Orchard said. The drug was never approved in the U.S.

ADA-SCIDis a condition marked by a mutation in the gene making the adenosine deaminase (ADA) enzyme, which is essential for maintaining normal white blood cells. ADA-SCID patients, with a dysfunctional immune system, have less than two years to live without effective intervention.

RELATED:Orchard licenses gene therapy tech from GSK

Strimvelis, originally developed by GSK and bought by Orchard in 2018, offers an option for patients who cant find a matched stem cell donor. It works by editing the patients own hematopoietic stem cells with the functional ADA gene. The cells arethen transferred back into the patient's bone marrow to mature and produce the normal ADA protein.

The therapy uses a gammaretrovirus as the vector to carry the gene. Problem is, retrovirus can incorporate their own genetic information into the human genome, causing unintended changes that can give rise to cancer. It is a known risk factor of gammaretroviral vector-based gene therapy and has been described as one of the important potential risks for Strimvelis in its EU approval.

Besides Strimvelis, Orchard is also developing OTL-101, which uses a lentivirus to insert a functional copy of the ADA gene into a patients cells. The drug is currently undergoing a registrational trial and has won breakthrough and orphan drug designations from the FDA.

All the gene therapy candidates in Orchards pipeline use lentiviral vectors that have been specifically designed to avoid insertional oncogenesis after administration, Orchard said, adding that no dangerous gene insertion has been reported around lentiviral vector-based stem cell gene therapy in any indication.

View post:
Orchard Therapeutics' gene therapy Strimvelis linked to a leukemia case - FiercePharma

→←